Lantern Pharma Inc.
- Market Cap (Standard market cap (price × shares outstanding) from the company profile — shown because the screener's float-computed cap is unavailable for this ticker.)
- $12.2M
- Price
- $0.91
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.58%
- Volume
- 223.5K
About
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Quick stats
Shares outstanding—
Computed float8.6M
Float / sharesUnknown
Cash runway (months)7.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001763950
AI Summary
AI-generated1/43
minorbullishclinical trial
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Lantern Pharma received Taiwan FDA protocol approval and lead-site IRB approval to open Part 2 of its Phase 2 HARMONIC trial of LP-300 in never-smoker, EGFR exon 21 L858R-mutant NSCLC patients.
Part 2 is a single-arm study extending LP-300 dosing from six to a maximum of eight cycles, supported by exploratory data showing 8.9-month median PFS in patients completing six cycles and a comparable safety profile at longer treatment durations.
Taiwan offers efficient enrollment given EGFR mutations in 55% of advanced lung adenocarcinomas there, and Lantern is exploring regional licensing and co-development partnerships for LP-300 in East Asia, where it estimates a $4 billion-plus annual market opportunity.
Red flags
- All clinical data cited are preliminary and exploratory with small patient cohorts (n=9 to n=16)
- LP-300 has not received FDA marketing approval for any indication